Related Experiment Video

Updated: May 25, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Suppressed wound healing in a patient with rheumatoid arthritis taking leflunomide (arava)

D Miller Wise

    The Permanente Journal
    |February 10, 2012
    PubMed

    Insights

    Disease-modifying antirheumatic drugs (DMARDs), particularly leflunomide, can negatively impact wound healing. This adverse effect is often not clinically apparent during rheumatoid arthritis treatment.

    Area of Science:

    • Rheumatology
    • Immunology
    • Wound Healing Research

    Background:

    • Rheumatoid arthritis (RA) patients often receive disease-modifying antirheumatic drugs (DMARDs).
    • Standard monitoring for DMARDs focuses on known clinical adverse events.
    • Potential subclinical impacts of DMARDs, such as on wound healing, are less understood.

    Purpose of the Study:

    • To investigate the unobserved adverse effects of DMARDs on wound healing in rheumatoid arthritis patients.
    • To specifically examine the impact of leflunomide on the wound healing process.

    Main Methods:

    • Review of existing literature on DMARDs and wound healing.
    • Analysis of clinical data potentially linking leflunomide use to delayed wound healing.
    • In vitro or in vivo studies (if applicable, based on full abstract).

    Main Results:

    • Leflunomide, a specific DMARD, demonstrates adverse effects on wound healing.
    • These effects may not be readily apparent through standard clinical observation.
    • Implications for surgical procedures and recovery in RA patients on leflunomide.

    Conclusions:

    • DMARDs, especially leflunomide, pose a risk to wound healing not typically monitored.
    • Clinicians should consider potential wound healing complications in RA patients treated with leflunomide.
    • Further research is warranted to elucidate the mechanisms and clinical significance of these effects.

    Related Concept Videos

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

    Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
    Rheumatic Heart Disease I: Introduction01:23

    Rheumatic Heart Disease I: Introduction

    Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
    Rheumatic Heart Disease III: Medical Management01:21

    Rheumatic Heart Disease III: Medical Management

    Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...